"Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "Andreas' deep expertise in endocrinology and proven track record of leading clinical development programs, from Investigational New Drug (IND) application to New Drug Application (NDA), make him an exceptional addition to our leadership team as we advance ...